Hilden, Germany

Orhan Aktas

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Hummingbird Diagnostics Gmbh. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Orhan Aktas: Innovator in Multiple Sclerosis Treatment

Introduction

Orhan Aktas is a notable inventor based in Hilden, Germany. He has made significant contributions to the field of medical science, particularly in the treatment and monitoring of multiple sclerosis (MS). His innovative approach focuses on utilizing miRNA for therapeutic applications.

Latest Patents

Orhan Aktas holds a patent for a method titled "MiRNA based treatment monitoring in multiple sclerosis." This invention relates to determining patient responses to therapeutic treatments for MS, monitoring the disease's progression, assessing relapse risks, and adjusting drug dosages accordingly. The methods are based on measuring the levels of specific miRNAs in test samples from patients. Additionally, the invention includes a kit designed for these purposes, enhancing the ability to manage MS effectively.

Career Highlights

Aktas is associated with Hummingbird Diagnostics GmbH, where he applies his expertise in developing innovative solutions for medical challenges. His work has been instrumental in advancing the understanding and treatment of multiple sclerosis.

Collaborations

Orhan Aktas collaborates with esteemed colleagues such as Andreas Keller and Markus Beier. Their combined efforts contribute to the ongoing research and development in the field of neurology.

Conclusion

Orhan Aktas stands out as a pioneering inventor in the realm of multiple sclerosis treatment. His innovative patent demonstrates a commitment to improving patient care and advancing medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…